Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation.

Seoul National University Hospital, Seoul, Korea.

Survival: monthsCountry:Korea
Toxiciy Grade:5City/State/Province:Seoul
Treatments:Chemotherapy, RadiationHospital:Seoul National University Hospital
Drugs:Journal:Link
Date:Nov 2010

Description:

Patients:
In this study, glioblastoma patients were separated into two different treatment groups. Group A consisted of 42 patients with a median age of 51.1 years, 35.7% of whom were male. Group B included 40 patients with a median age of 51.4 years and 27.5% male.

Treatment:
Patients in group A were treated with radiation therapy and the chemotherapy agent temozolomide.
Patients in group B were treated with radiation therapy and the chemotherapy agents nimustine, cisplatin, and temozolomide.

Toxicities:
The most severe adverse events in group A were of grade 3-4 and included 1 case of thrombocytopenia, 2 cases of headache, and 1 case of hemiparesis (weakness on one side of the body).
The most severe adverse events in group B were of grade 5, including death due to sepsis. Also reported were grade 3-4 neutropenia and thrombocytopenia (6 cases each) and grade 3-4 liver toxicity (2 cases).

Results:
The median overall survival for group A was 18.9 months. For group B, median overall survival was 28.4 months.

Correspondence: Dr. Hee-Won Jung; email: [email protected]



Back